Piezo1 channel causes lens sclerosis via transglutaminase 2 activation

• Published in: Experimental eye research Vol. 237; p. 109719
• Main Authors: Doki, Yuri, Nakazawa, Yosuke, Sukegawa, Miyu, Petrova, Rosica S, Ishida, Yuki, Endo, Shin, Nagai, Noriaki, Yamamoto, Naoki, Funakoshi-Tago, Megumi, Donaldson, Paul J
• Format: Journal Article
• Language: English
• Published: England 01.12.2023
• Subjects: Animals; Biological Transport; Ion Channels - metabolism; Mice; Presbyopia; Protein Glutamine gamma Glutamyltransferase 2; Sclerosis; Presbyopia; Animal model; Piezo1; Transglutaminase 2 (TGM2); Protein crosslinking
• ISSN: 0014-4835; 1096-0007
• DOI: 10.1016/j.exer.2023.109719

Presbyopia is caused by age-related lenticular hardening, resulting in near vision loss, and it occurs in almost every individual aged ≥50 years. The lens experiences mechanical pressure during for focal adjustment to change its thickness. As lenticular stiffening results in incomplete thickness changes, near vision is reduced, which is known as presbyopia. Piezo1 is a mechanosensitive channel that constantly senses pressure changes during the regulation of visual acuity, and changes in Piezo1 channel activity may contribute to presbyopia. However, no studies have reported on Piezo1 activation or the onset of presbyopia. To elucidate the relevance of Piezo1 activation and cross-linking in the development of presbyopia, we analysed the function of Piezo1 in the lens. The addition of Yoda1, a Piezo1 activator, induced an increase in transglutaminase 2 (TGM2) mRNA expression and activity through the extra-cellular signal-regulated kinase (ERK) 1/2 and c-Jun-NH2-terminal kinase1/2 pathways. In ex vivo lenses, Yoda1 treatment induced γ-crystallin cross-linking via TMG2 activation. Furthermore, Yoda1 eye-drops in mice led to lenticular hardening via TGM2 induction and activation in vivo, suggesting that Yoda1-treated animals could serve as a model for presbyopia. Our findings indicate that this presbyopia-animal model could be useful for screening drugs for lens-stiffening inhibition.